


RECEIVED

7001 DEC 11 A 6:05

21 November 2007

OFFICE OF INTERNATIONAL CORPORATE FINANCE  
SECURITIES AND EXCHANGE COMMISSION

07028592

US Securities and Exchange Commission  
Office of International Corporate Finance  
100 F Street, NE  
WASHINGTON, DC 20549  
USA

SUPPL

Mailstop: Room 3628  
Attention: Rule 12g3-2(b) Exemptions

Antisense Therapeutics Ltd hereby applies for amendment to Rule 12g3-2(b) Exemption (File Number 82-34841) for purposes of future electronic publication of the required disclosure documents.

We assume that providing this notification is all that is required for this amendment and advise that future documentation will now be published on our website [www.antisense.com.au](http://www.antisense.com.au).

Yours faithfully

Mark Diamond  
Managing Director

PROCESSED

DEC 12 2007

THOMSON  
FINANCIAL

END